Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iniparib

Next Previous
X
Search
Drug Profile

Iniparib

Alternative Names: BSI-201; SAR-240550

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator
  • Developer BiPar Sciences; National Cancer Institute (USA); Sanofi; TriAct Therapeutics
  • Class Antineoplastics; Benzamides; Iodobenzenes; Nitro compounds; Small molecules
  • Mechanism of Action Cell cycle inhibitors; H2AFX protein stimulants; Neoplasm protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma
  • Discontinued Brain metastases; Breast cancer; Fallopian tube cancer; Glioblastoma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer

Most Recent Events

  • 07 Jul 2021 Phase-II clinical trials in Glioma (Newly diagnosed) in USA (IV) prior to July 2021
  • 07 Jul 2021 Iniparib receives Orphan Drug status for Glioma in USA
  • 07 Jul 2021 TriAct Therapeutics completes phase II clinical trials in Glioma (Newly diagnosed) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top